The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Tumour Treating Fields (TTFields) present a completely different approach to cancer therapy, involving alternating electric ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Shareholders in the Nasdaq-listed German company, which is backed by billionaire investor and PayPal co-founder Peter Thiel, ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...